Company intelligence / Profile preview

Neurodegeneration Therapeutics

Charlottesville, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Neurodegeneration Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule therapies for neurodegenerative disorders. The company's primary research centers on the inhibition of Sirtuin 2 (SIRT2), a protein linked to the progression of diseases such as Parkinson's and Huntington's. By targeting the underlying mechanisms of protein misfolding and cellular stress, the company aims to provide disease-modifying treatments where current options are only symptomatic. Their lead programs are currently undergoing optimization and early-stage validation in animal models.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Neurodegeneration Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurodegeneration Therapeutics.

Explore the full profile